AETHLON MEDICAL INC(AEMD)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $1.6M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
AEMD Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for AETHLON MEDICAL INC (AEMD), a Healthcare sector company. AEMD is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $1.6m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), AETHLON MEDICAL INC reports net income of $-1.5M, free cash flow of $-1.9M. Top institutional holders of AEMD by reported 13-F value include HRT FINANCIAL, CITADEL ADVISORS, JANE STREET GROUP, based on the most recent SEC filings. AEMD trades on the Nasdaq exchange and files with the SEC under CIK 882291. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AEMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AETHLON MEDICAL INC directly from SEC EDGAR.
Net Income
Q2 2026
$-1.5M
Free Cash Flow
Q2 2026
$-1.9M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
+46.6% YoYOperating Income
+21.9% YoYEPS (Diluted)
+87.6% YoYTotal Assets
-13.9% YoYOp. Cash Flow
+8.5% YoYFree Cash Flow
+8.4% YoY| Metric | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $0.00 -100.0% | $574.2K +95.2% | $294.2K -55.4% | $659.1K |
| Net Income | $-7.2M +46.6% | $-13.4M -9.7% | $-12.2M -1.5% | $-12.0M -15.5% | $-10.4M -32.1% | $-7.9M |
| Operating Income | $-7.3M +21.9% | $-9.3M +26.1% | $-12.6M -6.2% | $-11.9M -14.2% | $-10.4M -32.1% | $-7.9M |
| EPS (Diluted) | $-10.61 +87.6% | $-85.77 -120.7% | $-38.87 -563.3% | $-5.86 -725.4% | $-0.71 | — |
| Total Assets | $6.3M -13.9% | $7.4M -10.8% | $8.2M -52.9% | $17.5M -9.8% | $19.4M +82.0% | $10.7M |
| Operating Cash Flow | $-7.0M +8.5% | $-7.6M +24.5% | $-10.1M +3.6% | $-10.5M -7.6% | $-9.8M -44.4% | $-6.8M |
| Free Cash Flow | $-7.0M +8.4% | $-7.6M +26.3% | $-10.4M +9.3% | $-11.4M -13.2% | $-10.1M -48.2% | $-6.8M |
Get alerted when AEMD's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for AETHLON MEDICAL INC including:
Top Institutional Holders of AEMD
HRT FINANCIAL LP
$59.0K72,743 shCITADEL ADVISORS LLC
$35.4K42,977 shJANE STREET GROUP, LLC
$32.0K38,880 shShay Capital LLC
$25.6K31,072 shVirtu Financial LLC
$23.0K27,815 shIkarian Capital, LLC
$11.8K14,364 shGEODE CAPITAL MANAGEMENT, LLC
$8.4K10,189 shScientech Research LLC
$8.3K10,054 shUBS Group AG
$7.3K8,876 shTower Research Capital LLC (TRC)
$5.2K6,331 sh
| Fund | Value | Shares |
|---|---|---|
| HRT FINANCIAL LP | $59.0K | 72,743 |
| CITADEL ADVISORS LLC | $35.4K | 42,977 |
| JANE STREET GROUP, LLC | $32.0K | 38,880 |
| Shay Capital LLC | $25.6K | 31,072 |
| Virtu Financial LLC | $23.0K | 27,815 |
| Ikarian Capital, LLC | $11.8K | 14,364 |
| GEODE CAPITAL MANAGEMENT, LLC | $8.4K | 10,189 |
| Scientech Research LLC | $8.3K | 10,054 |
| UBS Group AG | $7.3K | 8,876 |
| Tower Research Capital LLC (TRC) | $5.2K | 6,331 |
More Healthcare Companies
View all Healthcare →Put AEMD on your watchlist
Track score changes the day AETHLON MEDICAL INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is AEMD a good stock to buy?
13F Pro's AI-powered analysis of AETHLON MEDICAL INC (AEMD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AEMD are available on the AEMD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. AEMD is classified as a small company.
Which hedge funds own AEMD?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AEMD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of AETHLON MEDICAL INC's investment landscape.